EQS-News: Meridian Holdings Inc: Meridian Holdings Subsidiary Expanse Studios Enters Slovenian Market With Casino Portoroz Distribution Agreement

Meridian Holdings Inc. (NASDAQ: MRDN) reported Q2 2026 revenue of $50.2M, up 16% YoY, and adjusted EBITDA up 43% to $5.9M. GAAP net income was $2.2M versus a $3.6M loss a year earlier. Meridianbet revenue rose about 23% to $35.8M, with higher registrations, deposits and betting activity. Operating cash flow was $7.8M and net debt fell 65% to $9.4M.

Meridian Holdings Inc. (NASDAQ: MRDN) reported Q2 2026 revenue of $50.2M, up 16% YoY, and adjusted EBITDA of $5.9M, up 43%. GAAP net income attributable to MRDN was $2.2M versus a $3.6M loss a year earlier. Meridianbet revenue rose about 23% to $35.8M, and operating cash flow increased to $7.8M. Net debt fell 65% to $9.4M.

Meridian Holdings Inc. (NASDAQ: MRDN) reported Q2 2026 revenue of $50.2 million, up 16% year over year, and net income attributable to MRDN of $2.2 million, or $0.17 diluted EPS. Adjusted EBITDA rose 43% to $5.9 million. Total debt fell 45% to $26.7 million and net debt fell 65% to $9.4 million. The company expects 2H 2026 constant-currency revenue growth of 8% to 10%.

Meridian Holdings Inc./NV (MRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Meridian Holdings Reports Second Quarter 2026 Financial Results Revenue Up 16% Year-Over-Year to $50.2 Million Second Consecutive Quarter of GAAP Profitability with Net Income Attributable to MRDN of $2.2 Million and Diluted EPS of $0.17 Adjusted EBITDA Up 43% Year-O

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.